LNA antagonists targeting the androgen receptor

Details LNA antagonists targeting the androgen receptor LNA antagonists targeting the androgen receptor

2011-08-02

2011-08-02

Bowman, Amy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024310, C536S024330, C536S024500

Reexamination Certificate

active

07989429

ABSTRACT:
The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.

REFERENCES:
patent: 4914210 (1990-04-01), Levenson et al.
patent: 4962029 (1990-10-01), Levenson et al.
patent: 6733776 (2004-05-01), Li et al.
patent: 7067256 (2006-06-01), Roy et al.
patent: 7087229 (2006-08-01), Zhao et al.
patent: 2004/0235773 (2004-11-01), Zhao et al.
patent: 2005/0159376 (2005-07-01), McSwiggen et al.
patent: 2005/0164970 (2005-07-01), Li
patent: 0692972 (1994-10-01), None
patent: 97/11170 (1997-03-01), None
patent: WO97/11170 (1997-03-01), None
patent: 01/83740 (2001-11-01), None
patent: WO01/83740 (2001-11-01), None
patent: 2004/046160 (2004-06-01), None
patent: WO2004/046160 (2004-06-01), None
patent: 2004/063331 (2004-07-01), None
patent: WO 2004/063331 (2004-07-01), None
patent: 2005/027833 (2005-03-01), None
patent: WO2005/027833 (2005-03-01), None
patent: 2007/031081 (2007-03-01), None
patent: 2007/031091 (2007-03-01), None
patent: WO2007/031081 (2007-03-01), None
patent: WO2007/031091 (2007-03-01), None
patent: 2007/146511 (2007-12-01), None
patent: WO2007/146511 (2007-12-01), None
patent: 2008/034122 (2008-03-01), None
patent: 2008/034123 (2008-03-01), None
patent: WO2008/034122 (2008-03-01), None
patent: WO2008/034123 (2008-03-01), None
patent: 2008053314 (2008-05-01), None
patent: WO2008/053314 (2008-05-01), None
Kurreck et al., Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Research, vol. 30, pp. 1911-1918, 2002.
Eder et al., Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy, vol. 7, pp. 997-1007, 2000.
Beane et al., Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. Biochemistry vol. 46, oo. 7572-7580, 2007.
International Search Report issued in PCT/DK2008/000417 and dated Jun. 16, 2009.
Akinc, et al., “A combinatorial library of lipid-like materials for delivery of RNAi therapeutics,” Nature Biotechnology, vol. 26, pp. 561-569, 2008.
Freier & Altmann; “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DAN:RNA duplexes”, Nucl. Acid Research, vol. 25, pp. 4429-4443, 1997.
Manoharan, et al., “Novel Functionalization of the Sugar Moiety of Nucleic Acids for Multiple Labeling in the Minor Groove”, Tetrahedron Letters, vol. 32, pp. 7171-7174, 1991.
Monks, et al., “Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease”, PNAS, vol. 104, pp. 18259-18264, Nov. 13, 2007.
Uhlmann, Eugen, “Recent advances in the medicinal chemistry of antisense oligonucleotides”, Curr. Opinion in Drug Development, vol. 3, pp. 203-213, 2000.
Zhao et al., “A New Platform for Oligonucleotide Delivery Utilizing the PEG Prodrug Approach”, Bioconjugate Chemistry, vol. 16, pp. 758-766, 2005.
Zhao et al., “Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy”, J. of Controlled Release, vol. 119, pp. 143-152, 2007.
Beane et al., Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. Biochemistry vol. 46, pp. 7572-7580, 2007.
Akinc, et al., “A combinatorial library of lipid-like materials for delivery of RNAi therapeutics,” Nature Biotechnology, vol. 26, No. 5, pp. 561-569, 2008.
Freier & Altmann; “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DAN:RNA duplexes,”Nucl. Acid Research, vol. 25, No. 22, pp. 4429-4443, 1997.
Manoharan, et al., “Novel Funictionalization of the Sugar Moiety of Nucleic Acids for Multiple Labeling in the Minor Groove,”Tetrahedron Letters, vol. 32, No. 49, pp. 7171-7174, 1991.
Monks, et al., “Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease,” PNAS, vol. 104, No. 46, pp. 18259-18264, Nov. 13, 2007.
Uhlmann, Eugen, “Recent advances in the medicinal chemistry of antisense oligonucleotides,” Curr.Opinion in Drug Development, Vo. 3, No. 2, pp. 203-213, 2000.
Zhao, et al., “A New Platform for Oligonucleotide Delivery Utilizing the PEG Prodrug Approach,”Bioconjudate Chemistry, vol. 16, No. 4, pp. 758-766, 2005.
Zhao, et al.,“Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy,”J. of Controlled Release, vol. 119, pp. 143-152, 2007.

Affiliated with

Also associated with

Rating

LNA antagonists targeting the androgen receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LNA antagonists targeting the androgen receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LNA antagonists targeting the androgen receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2657025